Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...

Regeneron Pharmaceuticals Inc. failed to convince the Federal ... the Federal Circuit said in a precedential opinion issued Friday. “Amgen had discovered a way to prepare and formulate the active ...

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...

Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

A union for U.S. Agency for International Development contractors is asking a federal judge to intervene in any destruction ...

WASHINGTON — ABC’s “This Week” — Kevin Hassett, director of the White House National Economic Council; Sen. Adam Schiff, D-Calif.; Shawn Fain, president of the United Auto Workers. NBC's “Meet the ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Drucker honored District 16’s seven Regeneron Science Talent Search semifinalists and finalists. The Regeneron Science Talent Search scholars were selected from nearly 2,500 entrants from 795 ...

With a refreshed logo, a deepened brand philosophy and a unified vision across digital and broadcast, the WTA is reinforcing its position as the global leader in women’s sports and entertainment.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...